Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00509925
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Guildford, United Kingdom
Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00506662
Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 277
- Registration Number
- NCT00504673
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 712
- Registration Number
- NCT00503698
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom
Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00494988
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 187
- Registration Number
- NCT00491725
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00486278
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 81
- Registration Number
- NCT00476437
Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 470
- Registration Number
- NCT00474045
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT00472953
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
© Copyright 2024. All Rights Reserved by MedPath